Background/Aims: We evaluated prevalence and prognosis of mild anemia, defined as Hb (g/dl) 11-13.5 in males and 11-12 in females, in a prospective cohort of stage 3-5 chronic kidney disease (CKD) patients. Methods: We enrolled 668 consecutive patients in 25 renal clinics during 2003. Patients with frank anemia (Hb <11 or erythropoiesis-stimulating agents) at enrolment were excluded. Mild anemia was evaluated at two visits planned with an interval of 18 +/- 6 months to identify four categories: no anemia at both visits, mild anemia at visit 1 resolving at visit 2 (RES), mild anemia persisting at both visits (PER), and progression from no anemia or mild anemia at visit 1 to mild or frank anemia at visit 2 (PRO). Results: Mild anemia was present in 41.3% at visit 1 and 34.1% at visit 2. We identified PER in 22% patients, RES in 10%, and PRO in 26%. In the subsequent 40 months, 125 patients developed end-stage renal disease (ESRD) and 94 died. At competing risk model, PER predicted ESRD (hazard ratio, HR, 1.82, 95% confidence interval, Cl, 1.01-3.29) while PRO predicted both ESRD (HR 1.81, 95% Cl 1.02-3.23) and death (HR 1.87,95% CI1.04-3.37). Conclusion: In non-dialysis chronic kidney disease, mild anemia is prevalent and it is a marker of risk excess when persistent or progressive over time. Copyright (C) 2010 S. Karger AG, Basel

Prevalence and prognosis of mild anemia in non-dialysis chronic kidney disease: A prospective cohort study in outpatient renal clinics

SCIGLIANO, ROSELLA;AVELLA, Fabrizio;Postorino M;Santoro D;Castellino P;Rapisarda F;Fatuzzo P;
2010

Abstract

Background/Aims: We evaluated prevalence and prognosis of mild anemia, defined as Hb (g/dl) 11-13.5 in males and 11-12 in females, in a prospective cohort of stage 3-5 chronic kidney disease (CKD) patients. Methods: We enrolled 668 consecutive patients in 25 renal clinics during 2003. Patients with frank anemia (Hb <11 or erythropoiesis-stimulating agents) at enrolment were excluded. Mild anemia was evaluated at two visits planned with an interval of 18 +/- 6 months to identify four categories: no anemia at both visits, mild anemia at visit 1 resolving at visit 2 (RES), mild anemia persisting at both visits (PER), and progression from no anemia or mild anemia at visit 1 to mild or frank anemia at visit 2 (PRO). Results: Mild anemia was present in 41.3% at visit 1 and 34.1% at visit 2. We identified PER in 22% patients, RES in 10%, and PRO in 26%. In the subsequent 40 months, 125 patients developed end-stage renal disease (ESRD) and 94 died. At competing risk model, PER predicted ESRD (hazard ratio, HR, 1.82, 95% confidence interval, Cl, 1.01-3.29) while PRO predicted both ESRD (HR 1.81, 95% Cl 1.02-3.23) and death (HR 1.87,95% CI1.04-3.37). Conclusion: In non-dialysis chronic kidney disease, mild anemia is prevalent and it is a marker of risk excess when persistent or progressive over time. Copyright (C) 2010 S. Karger AG, Basel
Anemia; Chronic kidney disease; End-stage renal disease; Hemoglobin; Survival; Aged; Aged, 80 and over; Ambulatory Care Facilities; Anemia; Female; Glomerular Filtration Rate; Hemoglobins; Humans; Kaplan-Meier Estimate; Kidney Failure, Chronic; Longitudinal Studies; Male; Middle Aged; Predictive Value of Tests; Prevalence; Prognosis; Proportional Hazards Models; Prospective Studies; Renal Insufficiency, Chronic; Survival Analysis; Disease Progression
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/20.500.11769/370743
Citazioni
  • ???jsp.display-item.citation.pmc??? 11
  • Scopus 25
  • ???jsp.display-item.citation.isi??? 25
social impact